Skip to main content
Top
Published in: Cardiovascular Diabetology 1/2020

Open Access 01-12-2020 | Sudden Cardiac Death | Original investigation

Impact of type 2 diabetes mellitus on mid-term mortality for hypertrophic cardiomyopathy patients who underwent septal myectomy

Authors: Shengwei Wang, Hao Cui, Keshan Ji, Changpeng Song, Changwei Ren, Hongchang Guo, Changsheng Zhu, Shuiyun Wang, Yongqiang Lai

Published in: Cardiovascular Diabetology | Issue 1/2020

Login to get access

Abstract

Background

Type 2 diabetes mellitus is common in cardiovascular disease. It is associated with adverse clinical outcomes for patients who had undergone coronary artery bypass and valve operations. The aim of this study was to evaluate the impact of type 2 diabetes mellitus on the midterm outcomes of patients with hypertrophic cardiomyopathy who underwent septal myectomy.

Methods

We retrospectively analyzed the data of 67 hypertrophic cardiomyopathy patients with type 2 diabetes mellitus who underwent septal myectomy from two medical centers in China from 2011 to 2018. A propensity score–matched cohort of 134 patients without type 2 diabetes mellitus was also analyzed.

Results

During a median follow-up of 28.0 (interquartile range: 13.0–3.0) months, 9 patients died. The cause of death of all of these patients was cardiovascular, particularly sudden cardiac death in 3 patients. Patients with type 2 diabetes mellitus had a higher rate of sudden cardiac death (4.5% vs. 0.0%, p = 0.04). The Kaplan–Meier survival analysis revealed that the rates of predicted 3-year survival free from cardiovascular death (98.1% vs. 95.1%, p = 0.14) were similar between the two groups. However, the rates of predicted 3-year survival free from sudden cardiac death (100% vs. 96.7%, p = 0.01) were significantly higher in hypertrophic cardiomyopathy patients without type 2 diabetes mellitus than in those with type 2 diabetes mellitus. Furthermore, after adjustment for age and sex, only N-terminal pro-brain natriuretic peptide (hazards ratio: 1.002, 95% confidence interval: 1.000–1.005, p = 0.02) and glomerular filtration rate ≤ 80 ml/min (hazards ratio: 3.23, 95% confidence interval: 1.34–7.24, p = 0.047) were independent risk factors for hypertrophic cardiomyopathy patients with type 2 diabetes mellitus.

Conclusions

Hypertrophic cardiomyopathy patients with and without type 2 diabetes mellitus have similar 3-year cardiovascular mortality after septal myectomy. However, type 2 diabetes mellitus is associated with higher sudden cardiac death rate in these patients. In addition, N-terminal pro-brain natriuretic peptide and glomerular filtration rate ≤ 80 ml/min were independent risk factors among hypertrophic cardiomyopathy patients with type 2 diabetes mellitus.
Appendix
Available only for authorised users
Literature
1.
go back to reference American College of Cardiology Foundation/American Heart Association Task Force on P, American Association for Thoracic S, American Society of E, American Society of Nuclear C, Heart Failure Society of A, Heart Rhythm S, Society for Cardiovascular A, Interventions, Society of Thoracic S, Gersh BJ, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American college of cardiology Foundation/American heart association task force on practice guidelines. J Thorac Cardiovasc Surg. 2011;142(6):e153–203.CrossRef American College of Cardiology Foundation/American Heart Association Task Force on P, American Association for Thoracic S, American Society of E, American Society of Nuclear C, Heart Failure Society of A, Heart Rhythm S, Society for Cardiovascular A, Interventions, Society of Thoracic S, Gersh BJ, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: a report of the American college of cardiology Foundation/American heart association task force on practice guidelines. J Thorac Cardiovasc Surg. 2011;142(6):e153–203.CrossRef
2.
go back to reference Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.CrossRef Authors/Task Force m, Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Charron P, Hagege AA, Lafont A, Limongelli G, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: the task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014;35(39):2733–79.CrossRef
3.
go back to reference Wasserstrum Y, Barriales-Villa R, Fernández-Fernández X, Adler Y, Lotan D, Peled Y, Klempfner R, Kuperstein R, Shlomo N, Sabbag A, et al. The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. Eur Heart J. 2018;40(21):1671–7.CrossRef Wasserstrum Y, Barriales-Villa R, Fernández-Fernández X, Adler Y, Lotan D, Peled Y, Klempfner R, Kuperstein R, Shlomo N, Sabbag A, et al. The impact of diabetes mellitus on the clinical phenotype of hypertrophic cardiomyopathy. Eur Heart J. 2018;40(21):1671–7.CrossRef
4.
go back to reference Strain WD, Paldanius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;17(1):57.CrossRef Strain WD, Paldanius PM. Diabetes, cardiovascular disease and the microcirculation. Cardiovasc Diabetol. 2018;17(1):57.CrossRef
5.
go back to reference Halkos ME, Kilgo P, Lattouf OM, Puskas JD, Cooper WA, Guyton RA, Thourani VH. The effect of diabetes mellitus on in-hospital and long-term outcomes after heart valve operations. Ann Thorac Surg. 2010;90(1):124–30.CrossRef Halkos ME, Kilgo P, Lattouf OM, Puskas JD, Cooper WA, Guyton RA, Thourani VH. The effect of diabetes mellitus on in-hospital and long-term outcomes after heart valve operations. Ann Thorac Surg. 2010;90(1):124–30.CrossRef
6.
go back to reference Kogan A, Ram E, Levin S, Fisman EZ, Tenenbaum A, Raanani E, Sternik L. Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery. Cardiovasc Diabetol. 2018;17(1):151.CrossRef Kogan A, Ram E, Levin S, Fisman EZ, Tenenbaum A, Raanani E, Sternik L. Impact of type 2 diabetes mellitus on short- and long-term mortality after coronary artery bypass surgery. Cardiovasc Diabetol. 2018;17(1):151.CrossRef
7.
go back to reference Ram E, Kogan A, Levin S, Fisman EZ, Tenenbaum A, Raanani E, Sternik L. Type 2 diabetes mellitus increases long-term mortality risk after isolated surgical aortic valve replacement. Cardiovasc Diabetol. 2019;18(1):31.CrossRef Ram E, Kogan A, Levin S, Fisman EZ, Tenenbaum A, Raanani E, Sternik L. Type 2 diabetes mellitus increases long-term mortality risk after isolated surgical aortic valve replacement. Cardiovasc Diabetol. 2019;18(1):31.CrossRef
8.
go back to reference Wang S, Cui H, Yu Q, Chen H, Zhu C, Wang J, Xiao M, Zhang Y, Wu R, Hu S. Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction. J Thorac Cardiovasc Surg. 2016;152(2):461–8.CrossRef Wang S, Cui H, Yu Q, Chen H, Zhu C, Wang J, Xiao M, Zhang Y, Wu R, Hu S. Excision of anomalous muscle bundles as an important addition to extended septal myectomy for treatment of left ventricular outflow tract obstruction. J Thorac Cardiovasc Surg. 2016;152(2):461–8.CrossRef
9.
go back to reference Guo HC, Wang Y, Dai J, Ren CW, Li JH, Lai YQ. Application of 3D printing in the surgical planning of hypertrophic obstructive cardiomyopathy and physician-patient communication: a preliminary study. J Thorac Dis. 2018;10(2):867–73.CrossRef Guo HC, Wang Y, Dai J, Ren CW, Li JH, Lai YQ. Application of 3D printing in the surgical planning of hypertrophic obstructive cardiomyopathy and physician-patient communication: a preliminary study. J Thorac Dis. 2018;10(2):867–73.CrossRef
10.
go back to reference Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, et al. Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRef Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, et al. Recommendations for chamber quantification: a report from the American society of echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the european association of echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440–63.CrossRef
11.
go back to reference Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovascular imaging. 2012;5(4):370–7.CrossRef Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovascular imaging. 2012;5(4):370–7.CrossRef
12.
go back to reference Sabe MA, Sabe SA, Kusunose K, Flamm SD, Griffin BP, Kwon DH. Predictors and prognostic significance of right ventricular ejection fraction in patients with ischemic cardiomyopathy. Circulation. 2016;134(9):656–65.CrossRef Sabe MA, Sabe SA, Kusunose K, Flamm SD, Griffin BP, Kwon DH. Predictors and prognostic significance of right ventricular ejection fraction in patients with ischemic cardiomyopathy. Circulation. 2016;134(9):656–65.CrossRef
13.
go back to reference Geske JB, Driver CN, Yogeswaran V, Ommen SR, Schaff HV. Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy. Am Heart J. 2020;221:159–64.CrossRef Geske JB, Driver CN, Yogeswaran V, Ommen SR, Schaff HV. Comparison of expected and observed outcomes for septal myectomy in hypertrophic obstructive cardiomyopathy. Am Heart J. 2020;221:159–64.CrossRef
14.
go back to reference Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, Lever HM. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128(3):209–16.CrossRef Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, Lever HM. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128(3):209–16.CrossRef
15.
go back to reference López-de-Andrés A, de Miguel-Díez J, Muñoz-Rivas N, Hernández-Barrera V, Méndez-Bailón M, de Miguel-Yanes JM, Jiménez-García R. Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical mitral valve replacement in Spain (2001–2015). Cardiovasc Diabetol. 2019;18(1):135.CrossRef López-de-Andrés A, de Miguel-Díez J, Muñoz-Rivas N, Hernández-Barrera V, Méndez-Bailón M, de Miguel-Yanes JM, Jiménez-García R. Impact of type 2 diabetes mellitus in the utilization and in-hospital outcomes of surgical mitral valve replacement in Spain (2001–2015). Cardiovasc Diabetol. 2019;18(1):135.CrossRef
16.
go back to reference Brush JE, Siraj ES, Kemp CD, Liverman DP, McMichael BY, Lamichhane R, Sheehan BE. Effect of diabetes mellitus on complication rates of coronary artery bypass grafting. Am J Cardiol. 2019;124(9):1389–96.CrossRef Brush JE, Siraj ES, Kemp CD, Liverman DP, McMichael BY, Lamichhane R, Sheehan BE. Effect of diabetes mellitus on complication rates of coronary artery bypass grafting. Am J Cardiol. 2019;124(9):1389–96.CrossRef
17.
go back to reference Takeji Y, Shiomi H, Morimoto T, Furukawa Y, Ehara N, Nakagawa Y, Kato T, Tazaki J, Kato ET, Yaku H, et al. Diabetes mellitus and long-term risk for heart failure after coronary revascularization. Circul J. 2020;84(3):471–8.CrossRef Takeji Y, Shiomi H, Morimoto T, Furukawa Y, Ehara N, Nakagawa Y, Kato T, Tazaki J, Kato ET, Yaku H, et al. Diabetes mellitus and long-term risk for heart failure after coronary revascularization. Circul J. 2020;84(3):471–8.CrossRef
18.
go back to reference Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-alpha and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100–9.CrossRef Liu C, Feng X, Li Q, Wang Y, Li Q, Hua M. Adiponectin, TNF-alpha and inflammatory cytokines and risk of type 2 diabetes: a systematic review and meta-analysis. Cytokine. 2016;86:100–9.CrossRef
19.
go back to reference Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–77.CrossRef Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14(6):361–77.CrossRef
20.
go back to reference Grisanti LA. Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes. Front Physiol. 2018;9:1669.CrossRef Grisanti LA. Diabetes and arrhythmias: pathophysiology, mechanisms and therapeutic outcomes. Front Physiol. 2018;9:1669.CrossRef
21.
go back to reference Fuso L, Pitocco D, Antonelli-Incalzi R. Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension. Diabetes Metabol Res Rev. 2019;35(6):e3159.CrossRef Fuso L, Pitocco D, Antonelli-Incalzi R. Diabetic lung, an underrated complication from restrictive functional pattern to pulmonary hypertension. Diabetes Metabol Res Rev. 2019;35(6):e3159.CrossRef
22.
go back to reference Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;42(5):873–9.CrossRef Monserrat L, Elliott PM, Gimeno JR, Sharma S, Penas-Lado M, McKenna WJ. Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy. J Am Coll Cardiol. 2003;42(5):873–9.CrossRef
23.
go back to reference Di Salvo G, Pacileo G, Limongelli G, Baldini L, Rea A, Verrengia M, D’Andrea A, Russo MG, Calabro R. Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters. J Am Soc Echocardiogr. 2010;23(6):581–90.CrossRef Di Salvo G, Pacileo G, Limongelli G, Baldini L, Rea A, Verrengia M, D’Andrea A, Russo MG, Calabro R. Non sustained ventricular tachycardia in hypertrophic cardiomyopathy and new ultrasonic derived parameters. J Am Soc Echocardiogr. 2010;23(6):581–90.CrossRef
24.
go back to reference Coats CJ, Gallagher MJ, Foley M, O’Mahony C, Critoph C, Gimeno J, Dawnay A, McKenna WJ, Elliott PM. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J. 2013;34(32):2529–37.CrossRef Coats CJ, Gallagher MJ, Foley M, O’Mahony C, Critoph C, Gimeno J, Dawnay A, McKenna WJ, Elliott PM. Relation between serum N-terminal pro-brain natriuretic peptide and prognosis in patients with hypertrophic cardiomyopathy. Eur Heart J. 2013;34(32):2529–37.CrossRef
25.
go back to reference Song C, Wang S, Guo Y, Zheng X, Lu J, Fang X, Wang S, Huang X. Preoperative NT-proBNP predicts midterm outcome after septal myectomy. J Am Heart Assoc. 2019;8(4):e011075.CrossRef Song C, Wang S, Guo Y, Zheng X, Lu J, Fang X, Wang S, Huang X. Preoperative NT-proBNP predicts midterm outcome after septal myectomy. J Am Heart Assoc. 2019;8(4):e011075.CrossRef
26.
go back to reference Maekawa Y, Jinzaki M, Tsuruta H, Akita K, Yamada Y, Kawakami T, Hayashida K, Yuasa S, Murata M, Fukuda K. Improved renal function in a patient with hypertrophic obstructive cardiomyopathy after multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation. Int J Cardiol. 2015;181:349–50.CrossRef Maekawa Y, Jinzaki M, Tsuruta H, Akita K, Yamada Y, Kawakami T, Hayashida K, Yuasa S, Murata M, Fukuda K. Improved renal function in a patient with hypertrophic obstructive cardiomyopathy after multidetector computed tomography-guided percutaneous transluminal septal myocardial ablation. Int J Cardiol. 2015;181:349–50.CrossRef
Metadata
Title
Impact of type 2 diabetes mellitus on mid-term mortality for hypertrophic cardiomyopathy patients who underwent septal myectomy
Authors
Shengwei Wang
Hao Cui
Keshan Ji
Changpeng Song
Changwei Ren
Hongchang Guo
Changsheng Zhu
Shuiyun Wang
Yongqiang Lai
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/s12933-020-01036-1

Other articles of this Issue 1/2020

Cardiovascular Diabetology 1/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine